Search

Your search keyword '"Terrada, C."' showing total 12 results
Start Over Author "Terrada, C." Journal acta ophthalmologica
12 results on '"Terrada, C."'

11. Spontaneous branch artery occlusion in idiopathic retinitis, vasculitis, aneurysms, and neuroretinitis syndrome despite panretinal laser photocoagulation of widespread retina nonperfusion.

Author

Terrada C, Dethorey G, Ducos G, Lehoang P, Bodaghi B, and Souied EH

Subjects
Adult, Aneurysm diagnosis, Aneurysm surgery, Female, Fluorescein Angiography, Humans, Retinal Artery Occlusion diagnosis, Retinal Vasculitis diagnosis, Retinal Vasculitis surgery, Retinitis diagnosis, Retinitis surgery, Syndrome, Tomography, Optical Coherence, Aneurysm complications, Laser Coagulation, Retinal Artery, Retinal Artery Occlusion etiology, Retinal Vasculitis complications, Retinitis complications
Published
2011
Full Text
View/download PDF

12. Intravitreal bevacizumab as first local treatment for uveitis-related choroidal neovascularization: long-term results.

Author

Julián K, Terrada C, Fardeau C, Cassoux N, Français C, LeHoang P, and Bodaghi B

Subjects
Adult, Aged, Angiogenesis Inhibitors adverse effects, Antibodies, Monoclonal adverse effects, Antibodies, Monoclonal, Humanized, Bevacizumab, Choroidal Neovascularization etiology, Female, Follow-Up Studies, Fovea Centralis pathology, Humans, Intravitreal Injections, Male, Middle Aged, Retrospective Studies, Tomography, Optical Coherence, Treatment Outcome, Uveitis complications, Vascular Endothelial Growth Factor A antagonists & inhibitors, Visual Acuity physiology, Young Adult, Angiogenesis Inhibitors administration & dosage, Antibodies, Monoclonal administration & dosage, Choroidal Neovascularization drug therapy, Uveitis drug therapy
Abstract

Purpose: To report long-term results of intravitreal (IVT) bevacizumab as first local treatment for choroidal neovascularization (CNV) secondary to uveitis., Methods: Files of patients receiving 1.25 mg/0.05 ml bevacizumab as primary local treatment for CNV were retrospectively reviewed. Main outcomes were change in best-corrected visual acuity (BCVA) and central foveolar thickness (CFT), treatment-related adverse events, and number and frequency of injections., Results: Fifteen eyes from fifteen patients were included. Multifocal choroiditis and panuveitis were the diagnosis in seven, ampiginous choroiditis in two, and for six remaining, serpiginous choroiditis, sympathetic ophthalmia, Vogt-Koyanagi-Harada syndrome, punctuate inner choroidopathy, tuberculosis and idiopathic inflammation. In 13 eyes, neovascularization was subfoveal, and peripapillary in two. Intraocular inflammation was strictly controlled in all cases by the time of injections. BCVA improved from logMar 0.53 to logMar 0.29 in 12 eyes (80%), while CFT decreased from 239.06 to 195.2 μm in 13 (87%). Twelve eyes received more than one injection; mean number in this group was 4.25 (2-8), and frequency 1 every 12.97 weeks. There were no adverse events related to bevacizumab or the procedure. Median follow-up was 17.6 months (8-25)., Conclusions: First-intention IVT bevacizumab for inflammatory CNV showed transient improvement in BCVA and CFT, in eyes under controlled inflammation. Reinjection was needed in most cases. Further work should conclude about safety related to repeated injections., (© 2011 The Authors. Acta Ophthalmologica © 2011 Acta Ophthalmologica Scandinavica Foundation.)

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results